肺癌组织中耐药相关基因的表达水平及其临床意义

Overexpression and its clinical significance of multi-drug resistance associated genes in lung cancer tissues

目的 探讨肺癌组织耐药相关基因产物的表达水平及其临床意义。方法 采用免疫组化法S P对 60例肺癌组织及 30例癌旁肺组织中Pgp、MRP、GST π、TopoⅡ进行检测。结果 肺癌组织中Pgp、MRP、GST π、TopoⅡ表达阳性率分别为 40 .0 % (2 4 / 60 )、61 .7% (37/ 60 )、45 .0 % (2 7/ 60 )、81 .7% (49/ 60 ) ,均明显高于癌旁肺组织 (P <0 .0 1 ) ,上述耐药相关基因表达阳性率与肺癌TNM分期、病理类型、细胞分化程度、淋巴结转移状态均无明显关系 (P >0 .0 5)。结论 肺癌在癌变发生过程中其耐药相关基因均有不同程度的过度表达 ,联合检测这些基因的表达水平有助于指导化疗。

Objective To investigate the expression level and its clinical significance of the multi drug resistance (MDR) associated protein in lung cancer specimens. Methods The expression levels of Pgp, MRP, GST π and TopoⅡ of MDR associated protein were detected in 60 lung cancer samples and 30 paracancerous tissues by S P immunohistochemistry method. Results The positive rate of Pgp, MRP, GST π and Topo Ⅱ in the lung cancer tissues was 40.0% (24/60), 61.7% (37/60), 45.0% (27/60) and 81.7% (49/60) respectively, which was significantly higher than those in paracancerous tissues (P<0.01). No significant correlation was observed among the expression of multi drug resistance related protein and TNM staging, pathological type, cell differention and lymph node metastasis status (P>0.05). Conclusion Lung cancer has overexpression of multi drug resistant related genes during the oncogenesis. Combined detection of these genes may be useful for guiding the lung cancer chemotherapy.